摘要
目的探讨亚甲基四氢叶酸还原酶(MTHFR)C677 T基因多态性与新疆汉族乳腺癌的相关性.方法选取150例新疆汉族乳腺癌患者(试验组)和150例新疆汉族健康女性(对照组)为研究对象,用聚合酶链反应-限制性片段长度多态性方法检测MTHFR C677 T基因多态性,分析MTHFR C677 T基因多态性与乳腺癌的相关性.结果试验组和对照组MTHFR C677 T的CC基因型分别为29.33%(44例/150例)和66.00%(99例/150例),CT基因型分别为45.33%(68例/150例)和26.00%(39例/150例),TT基因型分别为25.33%(38例/150例)和8.00%(12例/150例),差异均有统计学意义(均P<0.05).试验组和对照组MTHFR C677 T的C等位基因频率分别为52.00%和79.00%,T等位基因频率分别为48.00%和21.00%,差异均有统计学意义(均P<0.05).结论MTHFR C677 T基因多态性与新疆汉族乳腺癌发生的具有相关性.
Objective To investigate the relationship between methylene tetrahydrofolate reductase(MTHFR)C677T gene polymorphism and breast cancer in Xinjiang Han populations.Methods A total of 150 breast cancer patients in Xinjiang Han populations(treatment group)and 150 healthy people(control group)were selected for the study.The polymerase chain reaction-restriction fragment length polymorphism was used to analyze the gene polymorphism of MTHFR C611T gene.The relationship between polymorphism of MTHFR C611T gene and breast cancer was analyzed.Results In treatment and control groups,the CC genotype of MTHFR C611T was 29.33%(44 cases/150 cases)and 66.00%(99 cases/150 cases),CT genotype was 45.33%(68 cases/150 cases)and 26.00%(39 cases/150 cases),while the TT genotype was 25.33%(38 cases/150 cases)and 8.00%(12 cases/150 cases),respectively.The differences were statistically significant(all P<0.05).The frequencies of C allele MTHFR C611T in the treatment and the control group were 52.00%and 79.00%,the frequencies of T allele were 48.00%and 21.00%,respectively,with statistically significant differences(all P<0.05).Conclusion Gene polymorphism of MTHFR C611T is associated with the occurrence of breast cancer in Xinjiang Han populations.
作者
张伟
刘新权
朱君玲
肖永彪
张军
李冬妹
曹玉文
张蕾
ZHANG Wei;LIU Xin-quan;ZHU Jun-ling;XIAO Yong-biao;ZHANG Jun;LI Dong-mei;CAO Yu-wen;ZHANG Lei(Department of Gastrointestinal Breast Vascular Surgery,The First Affiliated Hospital,Medical College of Shihezi University,Shihezi 832000,Xinjiang Uygur Autonomous Region,China;Department of Laboratory,The First Affiliated Hospital,Medical College of Shihezi University,Shihezi 832000,Xinjiang Uygur Autonomous Region,China;Department of General Surgery,The Fifth Corps Hospital,Bole 833400,Xinjiang Uygur Autonomous Region,China;Department of Osteopathic,The Fifth Corps Hospital,Bole 833400,Xinjiang Uygur Autonomous Region,China;Department of Pathology,First People's Hospital of Kashi,Kashi 844000,Xinjiang Uygur Autonomous Region,China;Department of Gastrointestinal Oncology Surgery,First People's Hospital of Kashi,Kashi 844000,Xinjiang Uygur Autonomous Region,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2021年第15期1978-1980,共3页
The Chinese Journal of Clinical Pharmacology
基金
第五师双河市科技计划课题资助项目(20YW01)。
